Carfilzomib

BreastfeedingPediatric
  • TRADE NAME: Kyprolis (Onyx)
  • INDICATIONS: Multiple myeloma
  • CLASS: Proteasome inhibitor
  • HALF-LIFE: ~1 hour

FDA APPROVAL DATE: 07/20/2012

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: D

Our database has 63 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
RENAL
HEMATOLOGIC
OTHER


Page last updated 06/12/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric